MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$6,641K
Net Income
-$23,757K
Net Profit Margin
-357.73%
EPS
-$0.18
Unit: Thousand (K) dollars
Revenue Breakdown
Roche DACAgreement
Roche Agreement
MKDGAgreement
Betta Agreement
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue from collaboration agreements
6,641
6,152
11,016
11,230
Research and development
24,471
24,606
24,982
25,989
General and administrative
8,593
9,331
9,179
8,920
Impairment of long-lived assets
-
-
-
10,733
Impairment loss on right-of-use asset
-
-
0*
-
Restructuring
-
-
0*
0
Total operating expenses
33,064
33,937
34,161
45,642
Loss from operations
-26,423
-27,785
-23,145
-34,412
Interest and other income, net
2,788
2,656
2,780
2,246
Total other income, net
2,788
2,656
2,780
2,246
Loss before income taxes
-
-
-20,365
-32,166
Income tax expense
-
-
121
-
Net loss
-23,635
-25,129
-20,486
-32,166
Unrealized (gain) loss on marketable securities
-
-
-37
-
Unrealized loss on marketable securities
-122
-372
-
117
Comprehensive loss
-23,757
-25,501
-20,523
-32,049
Basic EPS
-0.18
-0.2
-0.175
-0.44
Diluted EPS
-0.18
-0.2
-0.175
-0.44
Basic Average Shares
130,696,742
126,074,555
117,175,738
72,563,311
Diluted Average Shares
130,696,742
126,074,555
117,175,738
72,563,311
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$23,757K
(8.95%↑ Y/Y)
Interest and other
income, net
$2,788K
(12.37%↑ Y/Y)
Net loss
-$23,635K
(9.17%↑ Y/Y)
Unrealized loss on
marketable securities
-$122K
Total other income,
net
$2,788K
(12.37%↑ Y/Y)
Roche DACAgreement
$2,666K
Roche Agreement
$2,127K
(10.09%↑ Y/Y)
MKDGAgreement
$1,833K
(-46.53%↓ Y/Y)
Betta Agreement
$15K
(-72.22%↓ Y/Y)
Loss from operations
-$26,423K
(7.29%↑ Y/Y)
Revenue from
collaboration agreements
$6,641K
(2.75%↑ Y/Y)
Total operating
expenses
$33,064K
(-5.43%↓ Y/Y)
Research and development
$24,471K
(-6.59%↓ Y/Y)
General and
administrative
$8,593K
(-1.98%↓ Y/Y)
Buy us a coffee
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)